Teva Pharmaceutical Industries Ltd. $TEVA Stock Position Lifted by Hantz Financial Services Inc.

Hantz Financial Services Inc. lifted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 254.6% in the 3rd quarter, Holdings Channel.com reports. The fund owned 21,768 shares of the company’s stock after acquiring an additional 15,630 shares during the period. Hantz Financial Services Inc.’s holdings in Teva Pharmaceutical Industries were worth $440,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Phoenix Financial Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 9.4% in the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after purchasing an additional 3,533,800 shares during the period. National Pension Service grew its holdings in Teva Pharmaceutical Industries by 24.2% in the 3rd quarter. National Pension Service now owns 2,073,293 shares of the company’s stock worth $41,881,000 after buying an additional 404,526 shares in the last quarter. Oak Harvest Investment Services acquired a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $1,010,000. Harel Insurance Investments & Financial Services Ltd. raised its stake in Teva Pharmaceutical Industries by 12.9% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after acquiring an additional 4,306,363 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its stake in Teva Pharmaceutical Industries by 11.2% during the 3rd quarter. Teacher Retirement System of Texas now owns 697,574 shares of the company’s stock valued at $14,091,000 after acquiring an additional 69,994 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several recent analyst reports. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Scotiabank upped their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a report on Thursday, January 29th. Truist Financial increased their target price on shares of Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Jefferies Financial Group boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Finally, The Goldman Sachs Group increased their price objective on shares of Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, December 19th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.00.

Insider Buying and Selling

In other news, insider Mark Sabag sold 216,892 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total value of $6,231,307.16. Following the transaction, the insider directly owned 52,828 shares of the company’s stock, valued at $1,517,748.44. This trade represents a 80.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Richard Daniell sold 115,468 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the sale, the vice president owned 48,384 shares in the company, valued at $1,387,653.12. This represents a 70.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 422,060 shares of company stock worth $12,254,965 in the last quarter. 0.49% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $34.69 on Friday. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $37.35. The business’s fifty day moving average is $31.43 and its two-hundred day moving average is $23.87. The stock has a market capitalization of $39.79 billion, a P/E ratio of 28.91, a P/E/G ratio of 1.98 and a beta of 0.70. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.82 and a current ratio of 1.04.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.